AbstractArterial hypertension is an independent predictor of acute myocardial infarction. Nowadays, plasma levels of fibronectin and matrix metalloproteinase 9 are the markers of left ventricular remodeling.The objective of the research was to investigate potential antifibrotic effects of Quercetin in patients with acute myocardial infarction and arterial hypertension.Material and methods. 130 patients with myocardial infarction (63 individuals with concomitant arterial hypertension and 67 individuals without it) were observed. All the patients were divided into groups of basic treatment and additional prescription of Quercetin. Transthoracic echocardiogram was used. To evaluate plasma level of fibronectin and matrix metalloproteinase 9 the ELISA method was applied.Results. In all the patients, a significant decrease in fibronectin plasma levels was observed since the 28th day of treatment; however, it was more significant in group of additional prescription of Quercetin. Revascularization and pharmacological management of myocardial infarction resulted in the reduction in matrix metalloproteinase 9 plasma levels in all the patients since the 7th day of treatment; however, it was more significant in group of additional prescription of Quercetin. Conclusions. Quercetin possesses potential antifibrotic properties causing a reduction in plasma levels of fibronectin and matrix metalloproteinase 9 in patients with myocardial infarction and concomitant arterial hypertension.
Kintcher U. The burden of hypertension. EuroIntervantion. 2013;9:9-15. doi: 10.4244/EIJV9SRA3.
Kim HS, Kim DG. Effect of long-term resistance exercise on body composition, blood lipid factors, and vascular compliance in the hypertensive elderly men. J Exerc Rehabil. 2013;9(2):271-277. doi: 10.12965/jer.130010.
Thune JJ, Signorovitch J, Kober L, et al. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension. 2008;51(1):48-54.
Lee MG, Jeong MH, Lee KH, et al. Prognostic impact of diabetes mellitus and hypertension for mid-term outcome of patients with acute myocardial infarction who underwent percutaneous coronary intervention. J Cardiol. 2012;60:257-263. doi.org/10.1016/j.jjcc.2012.06.003
De Luca G, Dirksen MT, Spaulding C, et al. Impact of hypertension on clinical outcome in STEMI patients undergoing primary angioplasty with BMS or DES: insights from the DESERT cooperation. Int J Cardiol. 2014;175:50-54.
Reinstadler SJ, Stiermaier T, Eitel C, et al. Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction. J Cardiovasc Magnetic Resonance. 2017;18:80. doi:10.1186/s12968-016-0299-1.
Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction - from repair and remodeling to regeneration. Cell and Tissue Research. 2016;365(3):563-581. doi: 10.1007/s00441-016-2431-9
See F, Kompa A, Martin J, et al. Fibrosis as a therapeutic target post-myocardial infarction. Curr Pharm Des. 2005;11:477-487.
Akhlagni M, Bandy B. Mechanisms of flavonoid protection against myocardial ischemia–reperfusion injury. J Mol Cell Cardiol. 2009;46:309-317. doi: 10.1016/j.yjmcc.2008.12.003.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, et al. American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463. doi: 10.1016/j.echo.2005.10.005
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.